Key result
Acarbose significantly improved postprandial endothelial function compared to control in patients with newly diagnosed type 2 diabetes, with postprandial flow-mediated dilation of 6.8% vs 5.2% (p=0.0022).
Why the study?
Does acarbose improve postprandial endothelial dysfunction compared to nateglinide or no medication in patients with newly diagnosed type 2 diabetes?
Population
30 patients with newly diagnosed type 2 diabetes. Excluded: smokers, history of cardiovascular disease, and…
Comparison
Acarbose 300 mg/day for 12 weeks vs Nateglinide 270 mg/day for 12 weeks, or no…
Design
RCT, randomly assigned to receive one of the following treatments, open-label
Follow-up
12 weeks
Authors
Loading...
Acarbose may be favored over nateglinide for postprandial endothelial protection in new T2D; extends RCT evidence for alpha-glucosidase inhibitors on vascular surrogates.
RCT (n=30)
Open-label
Randomly assigned
Does acarbose improve postprandial endothelial dysfunction compared to nateglinide or no medication in patients with newly diagnosed type 2 diabetes?
Absolute Event Rate: 6.8% vs 5.2%
p-value: p=0.0022
Acarbose improves postprandial endothelial function more effectively than nateglinide in patients with newly diagnosed type 2 diabetes, likely by reducing postprandial hyperglycemia without increasing insulin secretion.
Kato et al. (2010) conducted an RCT in Newly diagnosed type 2 diabetes (n=30). Acarbose vs. No medication (control) or nateglinide 270 mg/day was evaluated on Postprandial flow-mediated dilation (FMD) of the brachial artery at 120 min after cookie load (p=0.0022). Acarbose significantly improved postprandial endothelial function compared to control in patients with newly diagnosed type 2 diabetes, with postprandial flow-mediated dilation of 6.8% vs 5.2% (p=0.0022).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: